Back to results
US 2026/0216199 A1Published application
Raf inhibitor and kras g12c inhibitor combination therapy
AssigneeErasca, Inc.
InventorsWei LIN, Jonathan LIM, Shannon MORRIS, Robert Field SHOEMAKER, Jae Hyun BAE, Zachary Miles PARTON
Life of this patent
Estimating the term…
Abstract
A pharmaceutical combination including a Raf inhibitor which is Compound of formula (I) or a pharmaceutically acceptable salt thereof, (b) a KRAS G12C inhibitor, and/or (c) trametinib.
Claims25
A pharmaceutical combination comprising (a) a Raf inhibitor which is Compound of formula (I)
- or a pharmaceutically acceptable salt thereof,
- and (b) a KRAS G12C inhibitor.
A pharmaceutical combination comprising (a) a Raf inhibitor which is Compound of formula (I)
- or a pharmaceutically acceptable salt thereof,
- (b) a KRAS G12C inhibitor,
- and (c) trametinib.
Dependencies are inferred from the claim text.